Regulatory Outlook finally claims FDA approval for AMD drug PharmaphorumAfter three knockbacks by the FDA, Outlook has finally pushed its therapy for age-related macular degeneration over the finish line in the US.OphthalmologyRead full story pharminent July 27, 2026 (Last updated: July 27, 2026) Pharmaphorum After three knockbacks by the FDA, Outlook has finally pushed its therapy for age-related macular degeneration over the finish line in the US. Ophthalmology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: D.C. Circuit Affirms HHS Authority Over 340B Rebate Models Related Stories Regulatory Lilly plans Q1 2027 filing for obesity triple retatrutide pharminent July 23, 2026 Regulatory GSK’s $10.6B Nuvalent bet pays off early as FDA approves lung cancer drug pharminent July 23, 2026 Regulatory FDA grants traditional approval to Novartis’ Fabhalta for IgAN pharminent July 17, 2026
